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Doctor Referral of Overweight People to Low Energy total diet 
replacement Treatment (DROPLET): pragmatic randomised 
 controlled trial
Nerys M Astbury, Paul Aveyard, Alecia Nickless, Kathryn Hood, Kate Corfield, Rebecca Lowe, 
Susan A Jebb
AbstrAct
Objective
To test the effectiveness and safety of a total diet 
replacement (TDR) programme for routine treatment of 
obesity in a primary care setting.
Design
Pragmatic, two arm, parallel group, open label, 
individually randomised controlled trial.
setting
10 primary care practices in Oxfordshire, UK.
ParticiPants
278 adults who were obese and seeking support to 
lose weight: 138 were assigned to the TDR programme 
and 140 to usual care. 73% of participants were re-
measured at 12 months.
interventiOns
The TDR programme comprised weekly behavioural 
support for 12 weeks and monthly support for three 
months, with formula food products providing 810 
kcal/day (3389 kJ/day) as the sole food during the 
first eight weeks followed by reintroduction of food. 
Usual care comprised behavioural support for weight 
loss from a practice nurse and a diet programme with 
modest energy restriction.
Main OutcOMe Measures
The primary outcome was weight change at 12 months 
analysed as intention to treat with mixed effects 
models. Secondary outcomes included biomarkers 
of cardiovascular and metabolic risk. Adverse events 
were recorded.
results
Participants in the TDR group lost more weight 
(−10.7 kg) than those in the usual care group 
(−3.1 kg): adjusted mean difference −7.2 kg (95% 
confidence interval −9.4 to −4.9 kg). 45% of 
participants in the TDR group and 15% in the usual 
care group experienced weight losses of 10% or 
more. The TDR group showed greater improvements in 
biomarkers of cardiovascular and metabolic risk than 
the usual care group. 11% of participants in the TDR 
group and 12% in the usual care group experienced 
adverse events of moderate or greater severity.
cOnclusiOns
Compared with regular weight loss support from a 
practice nurse, a programme of weekly behavioural 
support and total diet replacement providing 
810 kcal/day seems to be tolerable, and leads 
to substantially greater weight loss and greater 
improvements in the risk of cardiometabolic disease.
trial registratiOn
International Standard Randomised Controlled Trials 
No ISRCTN75092026.
Introduction
Excess adiposity is one of the main risk factors for 
morbidity and mortality.1 Weight loss ameliorates 
the risk and improves functioning and wellbeing,2 
with growing evidence that benefits can persist even 
if weight is regained.2 3 Primary care doctors have the 
opportunity to offer treatments for obesity at the scale 
required to have a discernible effect on prevalence of 
obesity and related diseases,4 and they are encouraged 
to screen patients and offer support for weight loss.5 
Despite this, doctors rarely provide such support.6
Good evidence shows that weight loss programmes 
provided in community groups by commercial 
providers are more effective than routine management 
delivered by primary care clinicians.7  8  9 Moreover, 
such programmes are cost effective and, over the long 
term, cost saving.8 Notwithstanding the population 
benefits, those who are referred lose only an additional 
2 kg compared with self help interventions, and people 
would benefit from interventions that lead to greater 
weight loss.10 One option is a total diet replacement 
(TDR) programme, combining a low energy diet with 
behavioural support. In a systematic review of trials we 
found that very low energy diets providing <800 kcal/
day led to statistically significantly greater weight loss 
WhAt Is AlreAdy knoWn on thIs topIc
A systematic review of trials recommending very low energy intakes (≤800 kcal/
day) showed that weight loss at one year was −10.3 kg (difference −3.9 kg, 95% 
confidence interval −6.7 to −1.1 kg) greater than the comparator behavioural 
support programmes
All the trials were conducted in specialist obesity clinics or research centres, 
however, and none were conducted in routine primary care
Results from the Diabetes in Remission Clinical Trial showed that a total diet 
replacement (TDR) programme with support provided by primary care staff for 
people with type 2 diabetes led to a similar weight loss, with almost half of 
patients in remission after one year
WhAt thIs study Adds
Compared with regular weight loss support from a practice nurse, a programme 
of weekly behavioural support and TDR providing 810 kcal/day (3389 kJ/day) 
led to substantially greater weight loss and greater improvements in the risk of 
cardiometabolic disease
Mean weight change at 12 months in the TDR group was −10.7 kg, a difference of 
−7.2 kg (95% confidence interval −9.4 to −4.9 kg) compared with usual care
Almost half (45%) of people achieved a weight loss of more than 10%
at one year
Nuffield Department of Primary 
Care Health Sciences, University 
of Oxford, UK
Correspondence to: NM Astbury 
nerys.astbury@phc.ox.ac.uk
Additional material is published 
online only. To view please visit 
the journal online.
cite this as: BMJ 2018;362:k3760 
http://dx.doi.org/10.1136/bmj.k3760
Accepted: 03 August 2018
 o
n
 20 M
arch 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3760 on 26 September 2018. Downloaded from 
RESEARCH
2 doi: 10.1136/bmj.k3760 | BMJ 2018;362:k3760 | the bmj
than behavioural weight management programmes 
based on usual foods.11 Currently, TDR programmes 
offer up to 1200 kcal/day, but similarly use formula 
food products as the sole source of nutrition alongside 
a behavioural support programme. Most trials of these 
programmes have been small scale, and conducted 
in research settings or specialist obesity clinics. A 
common but unsupported perception is that such 
programmes are unacceptable to most people, possibly 
unsafe, and lead to rapid weight regain, and guidelines 
do not recommend their use for general treatment of 
obesity.12 13
We investigated the effectiveness and safety of 
referral by a primary care doctor to a commercially 
provided low energy TDR programme compared with 
usual care. Consistent with the pragmatic nature of the 
trial we did not attempt to match treatment intensity 
in the two groups; rather, we compared the Cambridge 
Weight Plan programme, comprising specially 
formulated products and behavioural support, with 
the usual type of weight management programmes 
offered by primary care staff, based on dietary advice 
and behavioural support.
Methods
This trial was a pragmatic, individually randomised, 
two arm, open label, parallel design with a practice 
nurse allocating participants to a TDR programme 
or routine support.14 Participants gave written 
informed consent. On the advice of the independent 
trial steering committee, the protocol was amended 
after registration to reduce the number of secondary 
outcomes.
Participants and setting
We recruited participants from primary care practices 
in Oxfordshire, UK that were willing and able to offer 
a weight management programme within the practice. 
General practitioners searched their electronic health 
records for adults with a body mass index (BMI) of at least 
30 kg/m2 and whose health would benefit from weight 
loss and invited them by letter to participate. We excluded 
people who had received or were scheduled for bariatric 
surgery, those participating in a weight management 
programme, or those with contraindications to the 
TDR according to the protocol.14 (The supplementary 
appendix presents the full inclusion and exclusion 
criteria.) After telephone screening by researchers, 
eligible participants scheduled an appointment with a 
nurse at their local practice.
randomisation and masking
An independent statistician produced a computer 
generated randomisation list with 1:1 allocation 
using stratified block randomisation with randomly 
permuted block sizes of 2, 4, and 6, stratified by general 
practice and BMI (≤35 or >35). After the nurse had 
confirmed eligibility, participants were enrolled in the 
study and the allocation was revealed using an online 
randomisation programme to ensure full allocation 
concealment. Owing to the type of intervention it was 
not possible to blind participants, clinicians, or some 
of the researchers to treatment allocation.
interventions
The TDR programme was provided by Cambridge 
Weight Plan UK, which manages a network of 
counsellors providing behavioural support and food 
products.14 Participants were asked to contact a local 
counsellor who was aware of the research study and 
the protocol for the provision of formula food products, 
but who had not received any additional training to 
deliver the behavioural support programme. For the 
first 12 weeks, participants met with the counsellor 
weekly for support, which comprised goal setting, 
feedback, encouragement, reassurance, and problem 
solving. Participants replaced all food with four 
formula food products daily (soups, shakes, and bars), 
750 mL of skimmed milk, 2.25 L of water or other low 
or no energy drinks, and a fibre supplement; energy 
intake comprised 810 kcal/day (3389 kJ/day) (see 
supplementary table S1). After eight weeks, there was 
a four week stepwise reduction in use of the formula 
food products and reintroduction of conventional 
food based meals. During the weight maintenance 
phase from week 13 to 24, counsellors encouraged 
participants to attend monthly appointments and 
to consume one formula food product a day, with 
the remainder of the diet provided by food. If weight 
was regained, the protocol allowed for participants 
to return to the TDR stage for up to four weeks. This 
programme was free of charge to week 24.
Referral to a total diet replacement programme with support provided by a commercial 
provider is an effective intervention for the routine treatment of obesity.
©  BMJ 
Publishing group Ltd.Read the full article online http://bit.ly/BMJdrop
DROPLET trialVisual Abstract
Aged > yearsSourced from  GP practices
Randomisation
Weight change (mean) -7.2 kg 
Difference between arms
Patients with BMI >278
-10.7 kg -3.1 kg
Proportion reporting adverse events 51.5% 29.7%
Randomised controlled trial
Doctor Referral of Overweight People to 
Low Energy total diet replacement Treatment
Adverse events (moderate or worse) 11.2% 12.3%
138
Total Diet Replacement
 week programme.
 weeks TDR ( kcal/day).
 weeks food re-introduction.
Regular behavioural support.
140
Usual Care
Series of appointments
with a practice nurse
for behavioural weight
management advice.
Clinical significance
Defined as a  kg difference
between groups
Weight change from
baseline to  months
Primary outcome
21.8% less P<0.001
1.1% less P=0.85
P<0.001
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We asked clinicians to review drugs for any 
participants randomised to TDR who were receiving 
treatment for type 2 diabetes, or hypertension, or 
taking fibrates at the start of the programme, and at 
a scheduled assessment at one month and in routine 
reviews or as needed thereafter. We supplied clinicians 
with guidelines for this (see supplementary appendix). 
Data on the changes made to participants’ drugs were 
collected at follow-up visits, but changes to drugs were 
not one of the prespecified outcomes in the protocol. 
We plan on reporting this as a secondary analysis 
elsewhere.
For the comparator, participants followed each 
practice’s usual weight management protocol.14 We 
asked nurses to offer a programme for 12 weeks, 
at a frequency usual to the practice (eg, weekly or 
biweekly). Participants also received a 47 page booklet 
“So you want to lose weight . . . for good,”15 which 
includes information on goal setting, monitoring, 
and feedback, and advice about food types, portion 
control, and physical activity.
Participants were not prevented from attending 
other weight management groups, but no National 
Health Service referrals to these schemes were offered 
during the intervention period.
Procedures
We measured height at baseline only, blood samples at 
baseline and 12 months, and all other measurements 
at baseline and 3, 6, and 12 months. A digital scale 
(TANITA SC-240; Tanita, Amsterdam, Netherlands) 
was used to measure weight and body fat. Waist 
circumference was measured at the top of the iliac 
crest, and blood pressure was measured in triplicate 
using an automated blood pressure monitor and with 
participants seated, with the mean of the last two 
readings recorded. We recorded quality of life using two 
instruments: the EQ-5D and obesity and weight loss 
quality of life (OWL-QOL).16  17 Fasting blood samples 
were collected to measure blood glucose, insulin, and 
triglyceride levels and cholesterol fractions. Practice 
staff took the measurements at baseline and the 
research team at 3, 6, and 12 months. At 12 months we 
asked participants to self report if they had continued 
to try to manage their weight, and the methods they 
had used.
Outcomes
The primary outcome was change in body weight 
from baseline to 12 months. Prespecified secondary 
outcomes were change in body weight between 
baseline and three and six months, the proportion of 
participants achieving 5% or more and 10% or more 
weight loss at 12 months, and change in fat mass, 
low density lipoprotein cholesterol level, glycated 
haemoglobin (HbA1c), and systolic and diastolic blood 
pressure at 12 months.
Prespecified exploratory outcomes were change in 
fat mass and blood pressure at three and six months 
and in waist circumference at 3, 6, and 12 months. 
Change in concentrations of fasting triglycerides, 
high density lipoprotein cholesterol, glucose, and 
insulin from baseline to 12 months was measured. 
The HOMA (Homeostatic model assessment) model 
was used to measure insulin resistance (HOMA-IR), 
β cell function (HOMA-β), and insulin sensitivity 
(HOMA-S) and QRISK2 to calculate the change in 10 
year cardiovascular risk.18 19 We measured the change 
in self reported quality of life between baseline and 12 
months using the EQ-5D and OWL-QOL.16 17
The research team recorded adverse events 
through semistructured, open ended questioning 
of participants, by phone or in person, during the 
first three months of the programme. To allow for 
diagnostic delay of gallstone related events, we asked 
specific questions about such events at six months. 
These were coded using MedDRA version 18.1 and 
presented at the system organ class and preferred term 
level. In accordance with the statistical analysis plan, 
we present events that occurred in at least 2% of the 
participants, and all serious adverse events.
statistical analysis
We determined a difference of 4 kg weight loss 
between groups to be clinically relevant. Using data 
on standard deviation from published studies and 
assuming 90% power with a two sided significance of 
5%, and 20% loss to follow-up, we needed a sample 
of 270 people. Accounting for multiple testing of 
secondary outcomes, this gave 90% power to detect a 
standardised difference of 0.56 with 5% significance 
for the secondary outcomes.
We followed a statistical analysis plan approved 
by the independent trial steering committee before 
database lock. An independent trial statistician 
used PROC MIXED in SAS Version 9.4 to analyse the 
primary, secondary, and exploratory outcomes using 
an intention to treat analysis. We used linear mixed 
effects models with an unstructured correlation matrix 
for repeated measures and adjusted for baseline 
stratification variables, with practice set as a random 
effect. For binary outcomes, we used analogous 
logistic models. Before analysis of outcomes, we 
assessed the association between baseline variables 
and loss to follow-up at 12 months. Age and sex were 
associated with loss to follow-up and so were included 
as covariates as planned.
We assessed the sensitivity of the results to missing 
data using different imputation methods; baseline 
and last observation carried forward, completers only, 
multiple imputation, and a pattern mixture model 
assuming different degrees of missing not at random. 
To assess whether treatment effects differed by age, 
sex, BMI, socioeconomic status (based on participant’s 
postcode) and practice, we performed prespecified 
exploratory subgroup analyses. Following our 
statistical plan, we did not compare change in quality 
of life using inferential statistics.
Patient and public involvement
Our extensive public involvement activities have shown 
that a large proportion of people are interested to know 
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whether weight loss interventions are effective, and 
they welcome this kind of research. In a previous trial 
involving opportunistic offers of support for weight 
loss, patients overwhelmingly reported that this was 
appropriate and helpful.5 Members of the public who 
have expressed an interest in our research were invited 
to comment on the design of the study and the patient-
facing materials before ethical submission. Two lay 
people were members of the trial steering committee. 
Participants in the trial were offered the opportunity to 
hear the results of the study upon completion, and a 
lay summary and infographic have been provided.
results
Participants were recruited between 12 January 2016 
and 28 July 2016. Of 286 participants screened from 
10 practices, 278 were eligible and randomly allocated 
to either a total diet replacement (TDR) programme 
(n=138) or usual care (n=140). Follow-up was 
completed on 4 August 2017.
The average age of participants was 48 (SD 12) 
years, 61% were women, and 88% were white British. 
The average BMI was 37.2 (SD 5.4). On enrolment 23% 
had a diagnosis of hypertension and 15% had diabetes 
(table 1). Overall, 138 participants were randomised 
to the TDR group and 140 to usual care. After 
randomisation, four and two participants, respectively, 
withdrew consent for their data to be used. At 12 
months we followed-up 104 (78%) participants in the 
TDR group and 95 (69%) in the usual care group (fig 1).
In addition to the intervention set out in the 
protocol, during the weight maintenance phase (12-24 
weeks) 12 participants (9%) in the TDR group chose 
to pay for additional products or support. At the 12 
month follow-up, 104 participants in the TDR group 
and 95 in the usual care group provided information 
about ongoing weight control practices. Of these, 71 
(68%) in the TDR group reported trying to lose weight, 
27 (26%) were in contact with the TDR provider, and 
four were attending a community weight loss group. 
In the usual care group, 73 (77%) reported trying to 
lose weight, four were continuing to follow the plan 
recommended by the nurse, four were in contact with 
a TDR provider, and eight were attending a community 
weight loss group.
Primary outcome
Mean weight change at 12 months was −10.7 (SD 9.6) 
kg in the TDR group and −3.1 (7.0) kg in the usual care 
group (fig 2). The adjusted difference in mean weight 
change between the TDR and control groups was −7.2 
kg (95% confidence interval −9.4 to −4.9 kg; P<0.001).
Sensitivity analyses on loss to follow-up did not 
change the conclusion that the TDR programme 
led to greater weight change than usual care (see 
supplementary table S2). In the pattern mixture 
modelling (see supplementary fig S1), even assuming 
extreme bias in loss to follow-up in the TDR group or 
usual care group, there was a treatment difference 
of more than 5 kg in favour of TDR. Furthermore, 
there was no evidence that the intervention effect on 
weight differed by sex (P=0.22), age group (P=0.85), 
socioeconomic status (P=0.65), BMI (P=0.09), 
diabetes status (P=0.42), or practice (P=0.22) (see 
supplementary fig S2).
secondary outcomes
The TDR group had greater weight change at all 
time points before 12 months. At three months, the 
adjusted difference between groups was −9.6 kg (95% 
confidence interval −11.0 to −8.2 kg; P<0.001) and at 
six months was −9.6 kg (−11.6 to −7.7 kg; P<0.001).
Prespecified secondary outcomes included change 
in fat mass (measured at same time as body weight), 
which showed similar, albeit slightly smaller, 
differences in favour of the TDR group. Of those 
participants followed up at 12 months, 73% in the TDR 
group (n=104) and 32% in the usual care group (n=95) 
had lost 5% or more of their baseline body weight 
(adjusted odds ratio 6.5, 95% confidence interval 3.4 
to 12.2; P<0. 001), and 45% and 15%, respectively, 
had lost 10% or more of their baseline body weight 
(4.9, 2.4 to 9.9; P<0.001) (see supplementary fig S2). 
The number needed to treat to observe these benefits 
was 2.4 (95% confidence interval 1.8 to 3.5) and 3.3 
(2.4 to 5.4) for 5% or more and 10% or more body 
weight loss, respectively. In an addition to the protocol 
and in response to peer review, we report that 22% 
of participants in the TDR group and 4% in the usual 
care group lost 15% or more of their body weight at 12 
month follow-up.
table 1 | baseline characteristics of participants assigned to a total replacement diet 
(tDr) programme or usual care. values are means (standard deviations) unless stated 
otherwise
characteristics usual care group (n=140)* tDr group (n=138)*
Age (years) 47.4 (12.8) 48.2 (11.5)
Sex:
 No (%) women 84 (60) 81 (60.5)
 No (%) men 54 (39) 53 (40)
Ethnicity:
 No (%) white British 119 (86) 121 (90)
 No (%) not white British 19 (14) 13 (10)
Index of multiple deprivation 10th† 7.3 (2.0) 7.6 (2.0)
Weight (kg) 105.2 (20) 107.9 (18.9)
Height (cm) 168.7 (9.7) 169.2 (9.5)
Body mass index 36.8 (5.1) 37.6 (5.7)
Waist circumference (cm) 115.0 (12.5) 116.4 (13.5)
Body fat (%) 42.1 (7.7) 43.0 (7.8)
Blood pressure (mm Hg):
 Systolic 130.1 (15.8) 130.6 (16.4)
 Diastolic 81.3 (9.9) 83.1 (9.7)
No (%) with medical condition:
 Type 2 diabetes 20 (14) 21 (16)
 Hypertension 30 (22) 33 (25)
 HbA1c (mmol/mol) 38.6 (10.9) 39.6 (12.4)
 Fasting blood glucose (mmol/L) 5.6 (1.9) 5.9 (2.4)
 Fasting insulin (pmol/L) 105.3 (85.7) 96.4 (48.1)
Cholesterol (mmol/L):
 Total 5.1 (1.1) 5.1 (1.1)
 High density lipoprotein 1.2 (0.4) 1.2 (0.3)
 Low density lipoprotein 3.2 (0.9) 3.2 (0.9)
 Triglycerides (mmol/L) 1.6 (0.9) 1.6 (0.8)
*Two people in the usual care group and four in the TDR group withdrew consent for use of data after 
randomisation.
†Indicator of deprivation, with first 10th being most deprived and fifth 10th least deprived.
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At 12 months, participants in the TDR group had 
greater reductions in HbA1c (adjusted difference −2.2 
mmol/mol, 95% confidence interval −4.4 to 0.0 mmol/
mol; P=0.05) and diastolic blood pressure (−3.1 mm 
Hg, −5.5 to −0.7 mm Hg; P= 0.01), but no significant 
statistical difference was found in the reduction in 
systolic blood pressure (−2.9 mm Hg, −6.4 to 0.6 
mm Hg; P=0.1) or low density lipoprotein cholesterol 
level (0.0 mmol/L, 95% confidence interval −0.2 to 
0.2 mmol/L; P=0.8). Supplementary table S6 shows 
the outcomes for patients with a diagnosis of type 2 
diabetes at baseline.
exploratory outcomes
The change in waist circumference showed a similar 
pattern to that of changes in body weight and fat 
mass. Other exploratory outcomes assessed changes 
in glucose regulation, blood pressure, and other lipid 
fractions. These also reflected the secondary outcomes, 
showing marked improvements in the TDR group in 
glucose regulation, modestly greater reductions in 
blood pressure, and a slight improvement in triglyceride 
levels, but no difference in cholesterol fractions (table 
2). Thus, the TDR reduced overall cardiovascular risk 
to a greater extent than usual care (table 2).
Summary statistics are presented for exploratory 
analyses of the effect of treatment on quality of life. 
The TDR group showed greater improvement in EQ-5D 
and OWL-QOL score at six months and 12 months than 
the usual care group (table 2).
adverse events
Overall, adverse events were common and mild in both 
groups. Sixty nine (51%) participants in the TDR group 
and 41 (30%) in the usual care group experienced at 
least one adverse event (Fisher’s exact test: P<0.001) 
(see supplementary table S3), meaning that for every 
five people one would experience an adverse event due 
to the TDR. The most common adverse events where 
there was a greater incidence in the TDR group were 
constipation (1 in 7), fatigue (1 in 12), headache (1 
in 17), and dizziness (1 in 22) (table 3). Most of these 
adverse events were mild, with only 15 (11%) in the 
TDR group and 17 (12%) in the usual care group 
classed as moderate or severe, meaning that they 
interfered with normal functioning (Fisher’s exact test: 
P=0.85) (see supplementary table S2). One participant 
in the TDR group experienced the serious adverse 
event of admission to hospital for abdominal pain as a 
result of diverticulitis; evidence of any causal relation 
with the trial intervention was lacking because the 
adverse event occurred after randomisation but before 
the participant initiated the TDR programme.
discussion
Primary care referrals of people who are obese 
to treatment with a total diet replacement (TDR) 
programme in the community resulted in a weight 
reduction −7.2 kg (95% confidence interval −9.4 to −4.9 
kg) more than usual care at one year, with statistically 
significantly greater improvements in glucose control, 
diastolic blood pressure, and triglyceride levels, 
but not other lipid fractions. Among participants 
randomised to the TDR programme, 73% lost 5% or 
more of their baseline body weight and 45% lost 10% 
or more compared with 32% and 15% of participants 
in the usual care group, respectively. Although adverse 
events were more common in the TDR group, moderate 
or severe events occurred at similar frequency between 
the two groups.
strengths and limitations of this study
This trial tested the effectiveness of a TDR programme 
for the routine treatment of people who are obese, 
without specific comorbidities, in a generalist care 
setting. We recruited patients who are typical of 
those seen in primary care and who were seeking 
support for weight loss. We found that weight loss 
did not vary by age, sex, socioeconomic status, or 
Fig 1 | consort flowchart. bMi=body mass index; tDr=total diet replacement
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Fig 2 | Weight change over 12 months in intention to treat 
population. values represent mean (standard error of the 
mean)
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diabetes status, and together these factors suggest that 
this programme could be readily implemented and 
benefits realised across the population. In this study 
the intervention involved referral to a commercial 
provider. Previous studies have used specially trained 
health professionals or specialist research staff to 
provide the behavioural support, which is unlikely to 
be a scalable model for national roll-out across the NHS 
given current constraints on workforce. Loss to follow-
up was slightly lower than in most weight loss trials.8 
The observed difference in weight between treatment 
groups was greater than 5 kg in all sensitivity analyses. 
It is, however, limited by the relatively short duration 
of follow-up and the absence of direct evidence on 
the incidence of weight related disease or the cost 
effectiveness of the intervention. The formula food 
products are designed to be nutritionally complete, 
but we do not have data on nutrient intake during the 
programme or after the reintroduction of food, nor did 
we measure physical activity.
Funding for this trial was provided in large part by the 
provider of the intervention. This was an investigator 
initiated trial, however, with the idea for the trial 
and the protocol developed by the research team 
and the data analysed independently by a National 
Institute for Health Research accredited clinical trials 
unit, according to a prespecified statistical analysis 
plan with prior approval from the independent trial 
steering committee. This was a pragmatic trial where 
we estimated the net effect of an intervention, knowing 
that interventions may change other aspects of care.20 
Although we excluded people using drugs for weight 
loss, other drugs can affect body weight.21 However, 
randomisation is likely to have distributed comorbidities 
equally by arm and therefore adjustments in drugs that 
could affect body weight are likely to be similar.
table 2 | Primary, secondary, and exploratory outcomes by group allocation
Outcomes
Mean (sD) change from baseline adjusted difference 
(95% ci) P valueusual care group no tDr group no
3 months:
 Weight (kg)* −3.3 (4.2) 97 −13.3 (6.3) 114 −9.6 (−11.0 to −8.2) <0.001
 Waist circumference (cm)† −4.6 (4.9) 94 −13.1 (7.7) 111 −8.1 (−9.9 to −6.4) <0.001
 Fat mass (kg)† −3.0 (4.3) 95 −10.7 (6.2) 109 −7.1 (−8.6 to −5.6) <0.001
 Systolic blood pressure (mm Hg)† 3.5 (15.2) 96 −2.6 (15.8) 113 −5.8 (−9.1 to −2.4) 0.001
 Diastolic blood pressure (mm Hg)† 0.5 (8.9) 96 −4.4 (9.3) 113 −3.9 (−5.9 to −1.8) 0.001
6 months:
 Weight (kg)* −4.5 (6.2) 94 −15.1 (8.7) 108 −9.6 (−11.6 to 7.7) <0.001
 Waist circumference (cm)† −7.0 (7.2) 89 −15.4 (9.7) 102 −8.3 (−10.6 to −6.0) <0.001
 Fat mass (kg)† −4.8 (5.6) 86 −12.8 (9.6) 94 −7.9 (−9.9 to −5.9) <0.001
 Systolic blood pressure (mm Hg)† 4.0 (14.0 92 0.3 (16.7) 105 −3.3 (−6.9 to 0.3) 0.07
 Diastolic blood pressure (mm Hg)† 0.4 (9.3) 92 −3.5 (11.4) 105 −2.8 (−5.2 to −0.4) 0.02
 Quality of life:
 EQ-5D (index)† 0.03 (0.15) 73 0.07 (0.20) 92
 EQ-5D (VAS)† 7.0 (17.5) 74 15.5 (18.2) 93
 OWL-QOL† 10.6 (14.8) 74 17.4 (20.5) 92
12 months:
 Weight (kg)‡ −3.1 (7.0) 95 −10.7 (9.6) 104 −7.2 (−9.4 to −4.9) <0.001
 No (%) lost ≥5% weight 30 (31.6) 95 76 (73.1) 104 6.5§ (3.4 to 12.2) <0.001
 No (%) lost at least ≥10% weight 14 (14.7) 95 47 (45.1) 104 4.9§ (2.4 to 9.9) <0.001
 Waist circumference (cm)† −5.5 (7.3) 91 −10.5 (9.1) 99 −6.0 (−8.2 to −3.7) <0.001
 Fat mass (kg)* −4.1 (6.5) 93 −10.4 (8.5) 100 −5.8 (−7.9 to −3.7) <0.001
 Systolic blood pressure (mm Hg)* 2.9 (15.2) 93 −1.6 (16.4) 100 −2.9 (−6.4 to 0.6) 0.1
 Diastolic blood pressure (mm Hg)* 0.3 (9.3) 93 −4.2 (11.1) 100 −3.1 (−5.5 to −0.7) 0.01
 HbA1c (mmol/mol)* −1.0 (7.7) 75 −3.2 (8.8) 91 −2.2 (−4.4 to 0.0) 0.05
 Fasting glucose (mmol/L)† 0.1 (1.3) 75 −0.5 (1.8) 89 −0.4 (−0.8 to −0.1) 0.02
 Fasting insulin (pmol/L)† −10.4 (91.6) 72 −21.8 (41.8) 87 −18.0 (−32.0 to −4.0) 0.01
 HOMA-IR† −0.1 (1.5) 70 −0.5 (1.2) 86 −0.4 (−0.7 to-0.2) 0.003
 HOMA-β (%)† −15.0 (83.8) 70 −12.5 (39.7) 86 −9.8 (−22.9 to 3.4) 0.15
 HOMA-S (%)† −4.6 (70.4) 70 28.8 (47.5) 86 30.9 (16.4 to 45.5) <0.001
 Total cholesterol (mmol/L) 0.0 (0.9) 78 −0.2 (0.9) 91 −0.2 (−0.5, 0.04) 0.11
 HDL cholesterol (mmol/L)† 0.1 (0.3) 78 0.2 (0.3) 91 0.1 (0.0 to 0.2) 0.09
 LDL cholesterol (mmol/L)* −0.1 (0.7) 73 −0.1 (0.6) 87 0.0 (−0.2 to 0.2) 0.8
 Triglycerides (mmol/L)† 0.1 (0.6) 76 −0.3 (1.0) 89 −0.4 (−0.6 to −0.1) 0.002
 QRISK2 (%)† 0.0 (2.1) 88 −0.9 (2.6) 100 −1.0 (−1.7 to −0.3) 0.01
Quality of life:
 EQ-5D (index)† 0.07 (0.14) 93 0.09 (0.17) 100
 EQ-5D (VAS)† 9.2 (17.0 96 13.0 (18.7) 101
 OWL-QOL† 14.0 (16.7) 94 17.0 (20.9) 99
VAS=visual analogue scale; OWL-QOL=obesity and weight loss quality of life; HOMA=homeostatic model assessment; HOMA-IR=insulin resistance;  
HOMA-β=steady state β cell function; HOMA-S=insulin sensitivity; HDL=high density lipoprotein; LDL=low density lipoprotein.
*Secondary outcome.
†Exploratory outcome.
‡Primary outcome.
§Odds ratio.
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Our findings were obtained with one particular TDR 
programme and may have been different if participants 
were referred to another programme. However, 
the average weight change in this programme was 
similar to a study in which the diet was supported 
by a specially trained member of primary care staff22 
rather than a lay counsellor, and is comparable to the 
average weight loss in our meta-analysis of very low 
energy diets, which involved a variety of products 
and providers.11 Although the population we sampled 
was heterogeneous for socioeconomic status, it was 
not as deprived as the UK population as a whole, or 
those people with type 2 diabetes who were enrolled 
in a previous trial testing a TDR programme.22 The 
subgroup analysis showed no evidence that more 
deprived people received less benefit; however the 
power to detect such interactions was limited, so there 
is only weak evidence to suggest the treatment effect is 
similar in all socioeconomic groups. The proportion of 
participants from non-white ethnic groups, although 
representative of the local population, was too small to 
allow any meaningful subgroup analyses. Nonetheless, 
our study shows that this model of referral to an 
external provider, which is readily available at scale, is 
effective, and some evidence suggests it may generalise 
to other programme providers and across subgroups of 
the population.
comparisons with other studies
The TDR programme comprised 12 weekly support 
sessions followed by three further monthly sessions 
together with the use of food replacement products, and 
it is likely that both the support and food replacement 
were important. In the meta-analysis of very low energy 
diet programmes, a very low energy (<800 kcal/day) 
diet proved less effective than behavioural support 
that aimed for modest energy restriction, whereas 
programmes incorporating behavioural support 
alongside a very low energy diet were more effective 
than support programmes aimed at modest energy 
restriction.11 Currently, behavioural support for weight 
loss in primary care is constrained by limited interest 
in the topic, the lack of a defined programme, and 
competing demands, with the result that few patients 
receive support for weight loss.6 In this pragmatic trial 
the nurse programme was planned to comprise support 
over 12 weeks. This is likely to be more than the usual 
care received by most people who are obese in primary 
care; however, it provided considerably less input than 
the TDR programme. The level of behavioural support 
in the TDR group is comparable to that provided in 
intensive lifestyle intervention studies such as the 
US diabetes prevention programme, which offered 
16 sessions in the first 24 weeks. The 10.7 kg weight 
loss seen with TDR is greater than the 7 kg weight 
loss observed in the lifestyle group of the US diabetes 
prevention programme. Thus it appears that the weight 
loss observed in the TDR programme reflects both the 
TDR diet component and the support provided, and it 
is likely that either alone would be less effective than 
the package together.
Participants in this trial had a BMI of at least 30, 
and many were at risk of weight related morbidity—
although at baseline only 15% had diabetes and 
23% had hypertension. Evidence suggested that 
the intervention enhanced blood glucose control 
across several measures and there was a statistically 
significantly greater improvement in triglyceride 
levels although not in cholesterol fractions. The 
improvement in blood pressure at three months was 
statistically significant, but the difference was not 
significant thereafter for systolic blood pressure. 
We measured blood pressure on one occasion only, 
which gives an imprecise measure of the true value, 
and the trial was not sufficiently powered to detect 
the small difference that might be expected in blood 
pressure outcomes. Overall, the changes we observed 
were consistent with the magnitude of weight loss 
achieved.23 Data from other weight loss studies would 
suggest that this is likely to reduce the incidence of 
diabetes and cardiovascular disease and prevent 
premature mortality, commensurate with the greater 
reduction in 10 year cardiovascular risk seen in the 
TDR group.3  24 Changes in quality of life suggested 
greater improvements in the TDR group than usual 
care group, consistent with evidence from a systematic 
review that greater weight loss produces improvements 
in quality of life.25 In the longer term there may be 
additional QALY gains as a result of a lower incidence 
of disease. A systematic review of dietary interventions 
for weight loss for adults who were obese showed a 
significant reduction in risk of death (risk ratio 0.82, 
95% confidence intervals 0.71 to 0.95).24
table 3 | number (percentage) of participants allocated to usual care or total diet 
replacement (tDr) programme reporting an adverse event
adverse events*
usual care group 
(n=140)†
tDr group 
(n=138)† total
Gastrointestinal disorders:
 Abdominal discomfort 3 (2) 3 (2) 6 (2)
 Upper abdominal pain 0 (0) 3 (2) 3 (1)
 Breath odour 0 (0) 3 (2) 3 (1)
 Constipation 0 (0) 20 (15) 20 (7)
 Dry mouth 0 (0) 4 (4) 4 (1)
 Nausea 0 (0) 3 (2) 3 (1)
 Painful defaecation 0 (0) 4 (3) 4 (1)
General disorders: 
 Asthenia 0 (0) 3 (2) 3 (1)
 Fatigue (1) 12 (9) 13 (5)
 Influenza-like illness 4 (3) 3 (2) 7 (3)
 Thirst 0 (0) 3 (2) 3 (1)
Infections: 
 Lower respiratory tract infection 0 (0) 3 (2) 3 (1)
 Nasopharyngitis 7 (5) 4 (3) 11 (4)
Investigations: Scan 3 (2) 0 (0) 3 (1)
Nervous system disorders:
 Dizziness 2 (1) 6 (4) 8 (3)
 Headache 3 (2) 11 (8) 14 (5)
Psychiatric disorders:
 Irritability 0 (0) 3 (2) 3 (1)
Respiratory, thoracic, and mediastinal disorders:
 Oropharyngeal pain 2 (1) 2 (1) 4 (1)
*Events of any severity that occurred in more than 2% of the sample.
†Two people in the usual care group and four in the TDR group withdrew consent for use of data after 
randomisation.
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Anecdotal reports suggest that many people are 
concerned that TDR programmes with severe energy 
restriction will be unpopular and intolerable, but our 
results suggest otherwise. We used a similar recruitment 
method to other trials and achieved a similar uptake,8 
suggesting that people did not discriminate against 
this type of programme. Adverse events were more 
common in the TDR group but almost all mild and 
there was no statistically significant difference in 
events of moderate or greater severity. Clinicians who 
were initially unfamiliar with these programmes were 
able to adjust drugs appropriately. Together, these 
data suggest that TDR programmes would be effective, 
acceptable, and well tolerated if offered broadly. The 
system of referring patients to a commercial provider 
used in this study achieved similar absolute weight 
losses in the TDR groups as seen in DiRECT in people 
with type 2 diabetes who were from more deprived 
regions22 (DiRECT 10.0 (SD 8.0) kg, DROPLET 10.7 
(SD 9.6) kg). Referral to a commercial provider is 
already used for other types of weight loss support and 
offers the potential to reduce rather than increase the 
workload for healthcare professionals.
In this pragmatic trial, we accepted that participants 
may seek to lose weight in ways other than by following 
their assigned programme, including purchasing 
additional support. Although the TDR group were 
offered a rescue package that permitted participants 
to return to the TDR stage for up to four weeks at any 
time during weeks 13-24 if weight was regained, none 
took up this offer. However, 5% of those assigned to the 
TDR programme did not follow the protocol and paid 
for additional behavioural support and formula food 
products to continue weight loss rather than transition 
to the weight loss maintenance phase. At 12 months 
the proportions who reported attempting to lose weight 
were similar in both arms, with around seven in 10 
doing so. Of these, 38% in the TDR group remained in 
contact with a TDR consultant, presumably purchasing 
formula food products and receiving support, 
whereas only 5% of the usual care group reported 
continuing to follow the programme prescribed by 
a nurse. In addition, 6% of participants in the TDR 
group and 16% in the usual care group attended 
another commercial weight loss programme, usually a 
community weight loss group. Thus, these additional 
interventions probably contributed to overall weight 
loss and differences observed. This phenomenon is 
common to most weight loss trials; for example, at 
12 months—nine months after the end of a 12 week 
referral to a commercial weight loss programme—19% 
of people initially referred to the programme were 
paying for continuing support, compared with 9% 
who were allocated to a self help arm but nevertheless 
sought help at their own expense.8 Continued use of 
a successful programme seems to be more common 
in those who achieve initial success. In a weight loss 
maintenance trial enrolling people who had lost at 
least 5% of their body weight after a 12 week NHS 
referral to a commercial weight loss programme, 62% 
continued their programme over the next three months 
at their own expense and 42% continued during the 
next nine months.26 This suggests that the motivation 
created by a successful weight loss intervention, often 
prompted by an NHS funded intervention, can be an 
important stimulus to ongoing self management, 
which contributes to the health outcomes observed.
implications of this research
Current clinical guidelines recommend that this type 
of diet is reserved for people in whom short term weight 
loss is a priority—for example, before bariatric or knee 
replacement surgery, and they are not recommended 
as routine weight loss interventions.12  13 This 
presumably reflects concerns that weight loss is short 
lived. This trial shows that TDR leads to greater weight 
loss at one year than an intervention based on usual 
food, nine months after the TDR phase of treatment. 
Although, on average, some weight was regained after 
the programme end at 24 weeks until the final follow-
up, this also occurred in the usual care group. Most 
weight loss programmes report average weight regain 
after the end of the intervention,27 but a proportion 
of participants successfully maintain clinically 
important weight losses. Here 45% of participants in 
the TDR group had lost 10% of their baseline body 
weight six months after the end of the intervention, 
compared with only 15% in the usual care group. 
Despite a common supposition that weight regain is 
related to the rate of weight loss this is not supported 
by experimental evidence. In a study that directly 
tested this hypothesis, the rate of weight regain 
was similar for participants who were supported to 
achieve 15% or more weight loss using either a very 
low energy diet or more moderate energy restriction 
over a longer duration.28 Since the adverse health 
consequences of obesity relate to the duration of 
excess weight as well as its magnitude,3 29 the greater 
weight loss and comparable rates of average weight 
regain implies that the greater initial weight loss 
achieved with TDR programmes will be associated 
with greater improvements in long term health 
outcomes.
The NHS does not routinely offer this type of 
programme, and many primary care doctors are wary 
about supporting people who choose to use a TDR 
programme because they are unfamiliar with this 
approach or have concerns about the safety of such 
interventions. This trial should provide reassurance. 
General practitioners were given guidance to reduce, 
or stop, drugs for patients taking oral hypoglycaemic 
agents or antihypertensives at the start of the diet and 
to monitor these patients at four weeks. Weight loss at 
four weeks is a strong predictor of long term success, 
provides an opportunity to adjust drugs based on 
early weight change, and in this trial this approach 
did not give rise to an excess of adverse events.30 We 
included detailed elicitation of adverse events, and no 
unexpected or related adverse events occurred during 
the 12 weeks of TDR, and no cases of cholecystitis 
occurred during an extended reporting period to 24 
weeks.
 o
n
 20 M
arch 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k3760 on 26 September 2018. Downloaded from 
RESEARCH
the bmj | BMJ 2018;362:k3760 | doi: 10.1136/bmj.k3760 9
conclusion
A TDR programme combining nutritionally complete 
formula food products with behavioural support seems 
to be acceptable, well tolerated, and leads to greater 
weight loss with larger improvements in cardiovascular 
risk than currently available weight loss programmes 
offered in primary care.
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